Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.

about

Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis Immune-related adverse events of immune checkpoint inhibitors: a brief review

P2860

Q57491552-58D5D49D-9F40-4FA3-8CEF-8B45FD541E1B Q58756789-855902CE-5767-4A09-8730-C444F4F18F74 Q59126189-C1C2FB66-59BE-4E65-B289-C51600C5C383

P2860

Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.

Item

http://www.wikidata.org/entity/Q52655558

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Immune-related adverse events ...... atic review and meta-analysis.

@en

Immune-related adverse events ...... atic review and meta-analysis.

@nl

type

Item

label

Immune-related adverse events ...... atic review and meta-analysis.

@en

Immune-related adverse events ...... atic review and meta-analysis.

@nl

prefLabel

Immune-related adverse events ...... atic review and meta-analysis.

@en

Immune-related adverse events ...... atic review and meta-analysis.

@nl

P1476

Immune-related adverse events ...... matic review and meta-analysis

@en

P2093

Annie Yang

http://www.w3.org/2001/XMLSchema#string

Deborah Korenstein

http://www.w3.org/2001/XMLSchema#string

Niloufer Khan

http://www.w3.org/2001/XMLSchema#string

Renee L Gennarelli

http://www.w3.org/2001/XMLSchema#string

Shrujal Baxi

http://www.w3.org/2001/XMLSchema#string

Ziwei Wang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Toxicity management of immunotherapy for patients with metastatic melanoma

Toxicities of Immunotherapy for the Practitioner

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports

Nivolumab in previously untreated melanoma without BRAF mutation

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Psoriatic Arthritis.

P304

k793

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1136/BMJ.K793

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

360

http://www.w3.org/2001/XMLSchema#string

P50

Lindsay Boyce

P577

2018-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29540345

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

membrane proteins

P932

5851471

http://www.w3.org/2001/XMLSchema#string

Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.

about

P2860

P2860

Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P921

P932